Requires inpatient facilities to dispense at-risk individuals with opioid reversal drugs upon discharge.
Summary
A05840 would require certain hospitals and inpatient facilities to provide opioid reversal drugs, such as naloxone, to individuals who appear to be at risk for a substance use disorder when they are discharged. Under the bill, hospitals must already inform patients with a documented or suspected substance use disorder about available treatment services; this bill adds a requirement that, upon discharge, at-risk individuals receive at least two doses of opioid reversal drugs, including after emergency department discharge.
The bill also extends this discharge dispensing requirement to inpatient facilities operated or licensed by the Office of Addiction Services and Supports (formerly the Office of Alcoholism and Substance Abuse Services) and the Office of Mental Health. It would amend both the Public Health Law and the Mental Hygiene Law and take effect 180 days after becoming law. The measure is aimed at improving overdose prevention and ensuring patients leave care settings with immediate access to a life-saving medication.
Impact
The bill would create a new statutory obligation for hospitals and certain inpatient behavioral health facilities to dispense at least two doses of opioid reversal drugs to patients who appear to be at risk for substance use disorder at discharge. It would amend Public Health Law section 2803-u and add a new subdivision to Mental Hygiene Law section 29.15, expanding existing discharge notification requirements into a direct medication-dispensing mandate. Affected parties include hospitals, emergency departments, inpatient psychiatric facilities, addiction treatment facilities, and patients at risk of overdose.
Sentiment
The available voting history suggests strong bipartisan or at least broad committee support for the bill, with unanimous favorable votes in the Assembly Alcoholism and Drug Abuse Committee on both recorded occasions. No committee transcript is available, but the committee actions indicate the proposal was viewed positively as a public health and overdose-prevention measure. The bill’s framing around discharge planning and naloxone access aligns with generally favorable sentiment toward harm-reduction policies.
Contention
No explicit opposition is reflected in the provided materials, and the committee votes were unanimous. Potential points of contention, based on the bill’s substance, could include the cost and administrative burden on hospitals and inpatient facilities, questions about how facilities determine whether a patient “appears to be at risk,” and whether dispensing two doses in every qualifying discharge is operationally feasible. However, none of these concerns are documented in the supplied transcripts or vote summaries.